Results
Orchid Pharma Q4 FY26 Results and Strategic Updates
Orchid Pharma reported Q4 FY26 standalone revenue of INR238 crore and EBITDA of INR42.3 crore, signaling stabilization after a challenging year.
Management outlined strategic initiatives including the
